Patents Assigned to Pfizer Products Inc.
  • Polynucleotide molecules encoding neospora proteins
    Patent number: 6600027
    Abstract: The present invention provides isolated polynucleotide molecules comprising nucleotide sequences encoding GRA1, GRA2, SAG1, MIC1 and MAG1 proteins from Neospora caninum, as well as recombinant vectors, transformed host cells, and recombinantly-expressed proteins. The present invention further provides a polynucleotide molecule comprising the nucleotide sequence of the bidirectional GRA1IMAGI promoter of N. caninum. The present invention further provides genetic constructs based on the polynucleotide molecules of the present invention that are useful in preparing modified strains of Neospora cells for use in vaccines against neosporosis.
    Type: Grant
    Filed: March 25, 1999
    Date of Patent: July 29, 2003
    Assignees: Pfizer, Inc., Pfizer Products, Inc.
    Inventors: B. Rajendra Krishnan, Rebecca Madura, Christine Yoder, Becky Durtschi, David A. Brake
  • Use of corticotropin releasing factor antagonists and related compositions
    Patent number: 6589947
    Abstract: The present invention relates to compositions and methods of achieving a therapeutic effect including, the treatment or prevention of Syndrome X in an animal, preferably a mammal including a human subject or a companion animal, using a corticotropin releasing factor (CRF) antagonist alone or together with a glucocorticoid receptor antagonist.
    Type: Grant
    Filed: October 26, 2000
    Date of Patent: July 8, 2003
    Assignees: Pfizer Inc., Pfizer Products Inc.
    Inventors: Ernest S. Hamanaka, Yuhpyng Liang Chen
  • Process for preparing alkanesulfonyl pyridines
    Patent number: 6590103
    Abstract: A process for preparing alkanesulfonyl pyridines of the formula 1: is disclosed, wherein R1 is as defined herein. The compounds of formula 1 are useful in the preparation of pyridyl-substituted pyrazoles used in the treatment and alleviation of inflammation and other inflammation associated disorders.
    Type: Grant
    Filed: September 27, 2002
    Date of Patent: July 8, 2003
    Assignees: Pfizer, Inc., Pfizer Products, Inc.
    Inventors: Jolanta Nowakowski, Dieter Haag
  • Reactive crystallization method to improve particle size
    Patent number: 6558435
    Abstract: This invention provides a method of conducting a simultaneous chemical reaction and controlled crystallization of the product employing impinging fluid jet streams containing reactants capable of producing the product with desired particle size characteristics.
    Type: Grant
    Filed: May 23, 2001
    Date of Patent: May 6, 2003
    Assignees: Pfizer, Inc., Pfizer Products, Inc.
    Inventors: David J. Am Ende, Thomas C. Crawford, Neil P. Weston
  • Streptomyces avermitilis gene directing the ratio of B2:B1 avermectins
    Patent number: 6511841
    Abstract: The present invention relates to polynucleotide molecules comprising nucleotide sequences encoding an aveC gene product, which polynucleotide molecules can be used to alter the ratio or amount of class 2:1 avermectins produced in fermentation cultures of S. avermitilis. The present invention further relates to vectors, host cells, and mutant strains of S. avermitilis in which the aveC gene has been inactivated, or mutated so as to change the ratio or amount of class 2:1 avermectins produced.
    Type: Grant
    Filed: January 22, 2001
    Date of Patent: January 28, 2003
    Assignees: Pfizer, Inc., Pfizer Products, Inc.
    Inventors: Kim J. Stutzman-Engwall, Hamish McArthur, Yoshihiro Katoh
  • Methods related to Streptomyces avermitilis gene directing the ratio of B2:B1 avermectins
    Patent number: 6509159
    Abstract: The present invention relates to polynucleotide molecules comprising nucleotide sequences encoding the aveC gene product, which polynucleotide molecules can be used to alter the ratio or amount of class 2:1 avermectins produced in fermentation cultures of Streptomyces avermitilis. The present invention further relates to vectors, host cells, and mutant strains of Streptomyces avermitilis in which the aveC gene has been inactivated, or mutated so as to change the ratio or amount of class 2:1 avermectins produced.
    Type: Grant
    Filed: January 22, 2001
    Date of Patent: January 21, 2003
    Assignees: Pfizer Inc., Pfizer Products Inc.
    Inventors: Kim J. Stutzman-Engwall, Hamish McArthur, Yoshihiro Katoh
  • Leptospira vaccine antigens for the prevention of Leptospirosis
    Patent number: 6482924
    Abstract: Four antigenic preparations are provided, each of which contains a different protein from Leptospira which can be used immunologically in vaccines for leptospirosis caused by this organism. Also provided in the invention are polynucleotides encoding these four proteins and antibodies which bind the proteins for use in the diagnosis of leptospirosis.
    Type: Grant
    Filed: December 15, 1999
    Date of Patent: November 19, 2002
    Assignees: Pfizer Inc., Pfizer Products, Inc.
    Inventors: Eric A. Utt, Michael Stephen Willy, Don A. Dearwester
  • Processes and intermediates for preparing anti-cancer compounds
    Patent number: 6476040
    Abstract: The present invention relates to methods and intermediates for preparing compounds of the formula 1 and the pharmaceutically acceptable salts and solvates thereof, as well as structurally related compounds, wherein R1, R2 and R15 are as defined herein. The foregoing compounds are useful in the treatment of hyperproliferative disorders, such as cancers, in mammals.
    Type: Grant
    Filed: March 30, 2000
    Date of Patent: November 5, 2002
    Assignees: Pfizer Inc., Pfizer Products Inc.
    Inventors: Timothy Norris, Dinos P. Santafianos, Richard S. Lehner
  • Attenuated forms of bovine viral diarrhea virus
    Patent number: 6410299
    Abstract: The present invention is directed to a method of producing attenuated forms of bovine viral diarrhea (BVD) virus by mutating the Npro protease gene. The invention includes the attenuated viruses made by this method, antibodies generated using these viruses, and vaccines that can be used for immunizing cattle.
    Type: Grant
    Filed: August 29, 2000
    Date of Patent: June 25, 2002
    Assignees: Pfizer Inc., Pfizer Products Inc.
    Inventors: Xuemei Cao, Michael G. Sheppard
  • Combined treatment with keratinocyte growth factor and epidermal growth factor inhibitor
    Publication number: 20020061304
    Abstract: The present invention relates to compositions and methods for treating the epithelial toxicity caused by administering to a human cancer patient an epidermal growth factor receptor (EGFR) inhibitor. The pharmaceutical composition preferably comprises an EGFR inhibitor and a keratinocyte growth factor (KGF) in a pharmaceutically-acceptable carrier. The method of treatment comprises co-administering to the patient a therapeutically effective amount of KGF with the EGFR inhibitor.
    Type: Application
    Filed: March 15, 2001
    Publication date: May 23, 2002
    Applicant: PFIZER PRODUCTS INC. & OSI PHARMACEUTICALS, INC.
    Inventors: Penelope Elizabeth Miller, James Dale Moyer